A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Trial Profile

A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Omadacycline (Primary) ; Omadacycline (Primary) ; Linezolid; Linezolid
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Acronyms OASIS-1
  • Sponsors Paratek Pharmaceuticals
  • Most Recent Events

    • 06 Oct 2017 Data from sub-group analysis presenteded in a Paratek Pharmaceuticals Media Release.
    • 25 Sep 2017 According to a Paratek Pharmaceuticals media release, a subgroup analysis from this trial will be presented at IDWeek 2017.
    • 25 Apr 2017 Results reporting the efficacy results by clinical infection type and pathogen presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top